Abbott Laboratories
Tracked across 73 events · 1768 articles · First seen Feb 01, 2025 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Abbott Laboratories, through its Abbott Diabetes Care division, is at the center of this event due to the recall of its FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitor sensors. The malfunction has led to serious injuries and deaths, negatively impacting the company's reputation and potentially its stock price.
Dec 03, 2025 · 6 articles
Regulatory
Impact: Abbott Laboratories, Inc. received 510(k) clearance from the United States — Food and Drug Administration for its Lipoprotein(a) Molarity Assay, which is a significant step forward for the company in cardiovascular risk assessment.
Jun 18, 2026 · 6 articles
Business
Impact: Abbott Laboratories Limited has begun commercial supplies under its Rs. 825 crore CDMO mandate, marking a significant milestone in its transition toward long-duration global manufacturing partnerships and strengthening its manufacturing infrastructure.
Jul 01, 2026 · 6 articles
Business
Impact: Abbott Laboratories acquired Carolina Liquid Chemistries Corporation, expanding its diagnostic capabilities and product offerings. This acquisition is expected to create synergies and benefit laboratories of all sizes.
Jun 01, 2026 · 7 articles
Business
Impact: Abbott Laboratories is celebrating 25 years of its listing on the New York Stock Exchange, reaffirming its commitment to global governance, transparency, and innovation, and highlighting its trusted presence in the US pharmaceutical market.
May 28, 2026 · 7 articles
Business
Impact: Palomino achieved a key milestone by listing its common stock on the OTCQB Venture Market, enhancing its public profile and enabling electronic settlement. This supports its commercialization roadmap and future exchange listing.
Jul 13, 2026 · 7 articles
Business
Impact: Central company; reported 69% profit plunge, made Rs 240 crore provision, delayed semaglutide supplies, and faces securities investigation. Shares fell sharply.
Jul 09, 2026 · 23 articles
Business
Impact: Acquired Vega Links, expanding its market and technology portfolio; strengthened leadership and advisory board, positioning it as a leading AI interconnect company.
Aug 03, 2026 · 6 articles
Business
Impact: Neuland gains dedicated sterile API manufacturing capacity through Gland Pharma, supporting its growing demand and enhancing its CDMO capabilities. The corporate guarantee of ₹40 crore reflects its commitment.
Aug 05, 2026 · 6 articles
Business
Abbott Laboratories agreed to pay $670 million to settle a portion of the litigation alleging that its preterm infant formulas cause necrotizing enterocolitis (NEC), a deadly bowel disease. The settlement, announced on August 21, 2026,…
Impact: Abbott is the primary defendant, agreeing to pay $670 million to settle part of the NEC litigation. The settlement reduces legal uncertainty but does not resolve all claims, and the company continues to face thousands of lawsuits.
Aug 20, 2026 · 20 articles
Business
Impact: Abbott Laboratories, a wholly owned subsidiary of Cosmos Health, will manufacture 2.86 million units of three pharmaceutical products for Pharmex S.A. over five years, leveraging its EU-GMP-licensed facility.
Jun 17, 2026 · 7 articles
Business
Impact: As a major player in the CLIA market, Abbott Laboratories is strengthening its market position through innovation and strategic collaborations, with its ARCHITECT and Alinity i systems playing a major role in advancing high-throughput immunodiagnostic testing globally.
Jun 05, 2026 · 6 articles
Business
Impact: Abbott is collaborating with Medtronic — Medtronic MiniMed to commercialize its dual glucose-ketone sensors, expanding its reach in diabetes technology and potentially increasing revenue from its medical device segment.
Jun 03, 2026 · 7 articles
Business
Impact: Abbott Laboratories S.A., a wholly owned subsidiary of Cosmos Health, acquired the international patent application and will lead the efforts in pursuing patent protection and expanding nanotechnology-based product development platforms.
Jun 08, 2026 · 8 articles
Regulatory
Impact: Abbott will exclusively commercialize SimpleScreen CRC, expanding its colorectal cancer screening portfolio alongside Cologuard, and leveraging its existing infrastructure.
Jul 27, 2026 · 6 articles
Business
Impact: Abbott Laboratories, a wholly owned subsidiary of Cosmos Health>>>, manufactures C-Scrub Wash 4% and will be responsible for the production of the veterinary formulation, leveraging its existing infrastructure.
Jun 01, 2026 · 7 articles
Business
Impact: Key player; strong in in vitro diagnostics, the largest segment.
Jul 21, 2026 · 8 articles
Business
Multiple market research reports project significant growth in the global hematology analyzers and reagents market over the next several years. MarketsandMarkets forecasts growth from USD 7.57 billion in 2026 to USD 10.33 billion by 2031,…
Impact: Key player; market growth supports its diagnostics portfolio.
Jul 08, 2026 · 6 articles
Tech
Impact: Abbott Laboratories, Inc. is identified as a top company in the epigenetics market, indicating its presence and potential to benefit from market growth.
Jun 26, 2026 · 6 articles
Accidents
Impact: Abbott Laboratories is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
Business
Impact: Abbott Laboratories is a manufacturing site owned by Cosmos Health, identified as a non-core real estate asset with a value of approximately $15 million that could be monetized.
Jun 04, 2026 · 6 articles
Tech
Alphabet Inc.'s Alphabet Inc. announced a new health feature for its wearables that tracks insulin resistance over time, marking a first for consumer tech companies. The feature, announced Wednesday alongside new Pixel smartphones in New…
Impact: Its Lingo continuous glucose monitor is being integrated into Alphabet Inc. Health, potentially expanding its user base.
Aug 12, 2026 · 6 articles
Tech
Impact: Abbott Laboratories' Droplet Digital PCR technology is utilized in Biodesix's presentations and will co-present new data on MRD monitoring, indicating its role as a technology provider and collaborator.
Apr 06, 2026 · 6 articles
Business
Impact: Dr. Reddy celebrates its 25th anniversary of listing on the New York Stock Exchange, a milestone event.
May 29, 2026 · 11 articles
Business
Impact: Abbott Laboratories' FreeStyle Libre 2 Plus sensor is compatible with Insulet Corporation's Omnipod 5 in Spain, indicating a potential for increased sensor sales due to the new system's launch.
Jul 06, 2026 · 6 articles
Regulatory
Impact: Dr. Reddy's produces lower-cost generic semaglutide; the approval may pressure its market share in the obesity segment.
Jul 17, 2026 · 13 articles
Regulatory
Pulse Pharmaceuticals, a Hyderabad-based nano pharmaceutical drug delivery company, received approval from the India — Drugs Controller General of India (DCGI) for its nano-carrier entrapped Vitamin D3 oral dispersion. The approval, announced on August 20,…
Impact: Already a customer of Pulse's manufacturing, the approval may strengthen their supply relationship.
Aug 20, 2026 · 6 articles
Business
Impact: Abbott Laboratories' Dolby Vision and Dolby Atmos technologies are featured in the AORUS MASTER 16, contributing to its premium audio and visual experience.
May 27, 2026 · 45 articles
Business
Impact: Abbott Laboratories is one of several Indian generic drugmakers poised to enter the market with lower-priced versions of semaglutide once Semaglutide loses patent exclusivity.
Nov 11, 2025 · 6 articles
Business
Impact: Abbott Laboratories is conducting preliminary core examination for the Bracken well, contributing to the analytic phase of Max Power Mining's exploration.
Apr 02, 2026 · 7 articles
+ 43 more events
View on Dashboard
100
Abbott Laboratories reached settlementAbbott settles preterm...
80
Abbott Laboratories dropped appealAbbott settles preterm...
70
Abbott Laboratories faced lawsuits Reckitt Benckiser — Mead JohnsonAbbott settles preterm...
70
Reckitt Benckiser — Mead Johnson faced lawsuits Abbott LaboratoriesAbbott settles preterm...
60
Alphabet Inc. integrating Abbott Lingo Abbott LaboratoriesGoogle Wearables Track...
40
Abbott Laboratories suggested product unavailabilityAbbott settles preterm...
30
Abbott Laboratories denied liabilityAbbott settles preterm...
Astec LifeSciences
no relationship
↔
Abbott Laboratories
Abbott Laboratories and Astec LifeSciences do not have a direct business-to-busi
Astec LifeSciences
no relationship
↔
Abbott Laboratories
Astec LifeSciences and Abbott Laboratories do not have a direct business-to-busi
Sun Pharma
competitor
↔
Abbott Laboratories
Abbott Laboratories competes directly with Sun Pharma in the global pharmaceutic
Sun Pharma
competitor
↔
Abbott Laboratories
Sun Pharmaceutical Industries acts as a major competitor to Abbott Laboratories
+ 8 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track Abbott Laboratories live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard